FAQs on the Use of Asparaginase Therapy in Young and Older Adults With Acute Lymphoblastic Leukemia

In this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with acute lymphoblastic leukemia.Topics discussed include:Practical considerations for management of allergy-like reactions and hypersensitivity to asparaginaseIndirect methods for measuring asparaginase activityStrategies to mitigate adverse events with asparaginase treatment, including hepatotoxicity, pancreatitis, and thrombosisConsiderations for use of asparaginase in special populations (eg, high BMI, older age)Presenters:Program DirectorDaniel J. DeAngelo, MD, PhDProfessor of MedicineDepartment of MedicineHarvard Medical SchoolChief of the Division of LeukemiaDepartment of Medical OncologyDivision of Hematologic MalignanciesDana‐Farber Cancer InstituteBoston, MassachusettsEmily Curran, MDAssistant ProfessorDivision of Hematology/OncologyUniversity of Cincinnati Cancer InstituteCincinnati, OhioKjeld Schmiegelow, MD, DMSciProfessorDepartment of Pediatric OncologyRighospitalet University HospitalCopenhagen, DenmarkContent based on an online CME program supported by an independent educational grant from Jazz Pharmaceuticals.Link to full program:http://bit.ly/3YXkLyj